The purpose of this study is to establish a recruitment database of individuals who have contacted the research staff in the department of dermatology expressing interest in participating in clinical research and requesting to be contacted if eligible to participate.

What is the purpose of this study?This study is being done to compare how well Zopocianine (OTL78) in combination with Near InfraRed (NIR) fluorescent imaging may improve the detection of malignant (growing in an uncontrolled way) tissue in adult subjects undergoing prostatectomy and lymph node dissection for biopsy confirmed prostate cancer.THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, patients are not actively “recruited,” but are screened by their physician for appropriate clinical trial(s) at the time of their routine clinic visit. Occasionally, a patient may be a self-referral or physician referral, but are still screened for appropriate clinical trials at the time of their routine clinic visit. PI and staff may send copies of relevant consent forms to these patients to look over prior to actually consenting or enrolling them. This may take place at the patient's visit at which the consent is presented or the patient's next visit to the outpatient hematology/oncology clinic.  Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632</div>

What is the purpose of this study?This is an observational study of patients with PSC to address knowledge gaps in the clinical presentation, natural history, epidemiology, patient experience and treatment of pruritus in PSC.  Sub-study 1 is the retrospective component (collecting data from 1810808663). Sub-study 2 is visit one. Sub-study 3 consists of all of the visits after that initial visit.  THIS STUDY IS ENROLLING BY INVITATION ONLY - The retrospective data collection part of this study (sub-study 1), will have no subject interaction. For sub-studies 2 and 3, participants will be recruited during their clinic visits by the research team.

What is the purpose of this study?This study aims to understand how a new eye treatment, Pegcetacoplan, affects levels of certain proteins in the blood (complement proteins) that are linked to age-related macular degeneration and to measure the progression rate of the disease based on OCT landmarks using standard pretrained AI model. By tracking these changes, we hope to identify ways to predict how well patients with age-related macular degeneration will respond to the treatment and improve outcomes for both eyes.THIS STUDY IS ENROLLING BY INVITATION ONLY - Participants will be identified during their scheduled visits at Indiana University eye clinics, focusing on patients diagnosed with geographic atrophy related to age-related macular degeneration, who are candidates for recieving the FDA-approved drug (Pegcetacoplan). Potential subjects will be approached during routine clinic visits by trained research staff. Eligible individuals will be seen during routine clinical practice by Dr Amir Hajrasouliha (PI) who will explain the study details and assess their interest in participation.

What is the purpose of this study?Type 1 retinopathy of prematurity in zone I represents the most severe type of ROP and hashe worst prognosis. It is unknown whether low-dose bevacizumab will be successful in the severe cases. Also unknown is the timing and extent of peripheral retinal vascularizationw-dose bevacizumab compared with the standard dose. The current study will evaluate whether doses of 0.063 mg and 0.25mg are effective as treatment for type 1 ROP, with ROP andvessels all in zone I. THIS STUDY IS ENROLLING BY INVITATION ONLY

What is the purpose of this study?Diabetic retinopathy is characterized by damage to retinal blood vessels. At present, there is no diagnostic marker reflecting retinal vascular health. By studying RNA content (genetic material that makes proteins) in highly specialized cells in circulating blood resembling blood vessels, we will discover biomarker of diabetic retinopathy THIS STUDY IS ENROLLING BY INVITATION ONLY - Subjects will be recruited during their routine eye appointment visiting our clinics at one of the following facilities: (i) Glick Eye Institute, (ii) Springmill clinic, and (iii) Eskenazi Hospital Eye Clinic. Dr. Amir Hajrasouliha and study coordinators will help with patient identification and enrollment. After routine eye examination, the subject’s eligibility will be assessed, and the study will be discussed. For subjects who are eligible for the study, the study protocol will be discussed with the patient by a study investigator and clinic coordinator. If the subject agrees, they will be enrolled in the study during the same appointment.